Remove society womens-health
article thumbnail

STAT+: Drug shortages reached a record high as 2023 drew to a close

STAT

These include oxytocin, which is used during childbirth; Rho(D) immune globulin, which helps some women during pregnancy; standard-of-care chemotherapy, pain and sedation medicines; and ADHD pills. Unresolved shortages have, in fact, been hovering above 300 for more than a year as numerous basic and life-saving medicines are in short supply.

article thumbnail

Utrogestan accepted as HRT in Scotland

European Pharmaceutical Review

The Scottish Medicines Consortium (SMC) has accepted Utrogestan, the only adjunctive micronised progesterone available as hormone replacement therapy (HRT) for use alongside any oestrogen-only HRT for women with an intact uterus. Adjunctive micronised progesterone – a menopause milestone for Scottish women.

105
105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Utrogestan approved as HRT in Scotland

European Pharmaceutical Review

The Scottish Medicines Consortium (SMC) has approved Utrogestan, the only adjunctive micronised progesterone available as hormone replacement therapy (HRT) for use alongside any oestrogen-only HRT for women with an intact uterus. Adjunctive micronised progesterone – a menopause milestone for Scottish women.

97
article thumbnail

The History of Women in Healthcare

Pharma Marketing Network

The history of women in healthcare is a story of struggle and triumph, of discrimination and determination. Throughout the centuries, women have played a vital role in providing care and comfort to the sick and the injured, and in advancing the field of medicine.

52
article thumbnail

Combination treatment could minimise cancer relapse risk

European Pharmaceutical Review

percent for women who were treated with only hormone therapy Distant-free survival rates in the trial were 90.8 The research was published in New England Journal of Medicine and the results were presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. percent recurrence-free survival, compared to 88.6

77
article thumbnail

Clinical trial to reduce cardiac damage from breast cancer therapy set to launch in EU

Hospital Pharmacy Europe

Women receiving breast cancer therapy across six clinical centres in Europe will be enrolled in a study to determine whether behavioural and psychological interventions can reduce the cardiac damage from anti-cancer therapies. It is already known that breast cancer survivors have an estimated 32% higher risk of cardiovascular disease.

article thumbnail

STAT+: More physicians are calling for fallopian tube removal to prevent ovarian cancer

STAT

Ovarian cancer has long been one of the deadliest cancers to strike women. Fewer than half of women survive 5 years past their diagnosis, and 80 percent have no known risk factors. ” A woman’s risk of developing the disease is 1 in 78, according to the  American Cancer Society.